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Abstract
Background: Data on the epidemiology and costs related to herpes zoster (HZ) and postherpetic neuralgia (PHN)
in Spain are scarce; therefore, studies are needed to evaluate the epidemiological and economic impact of HZ and
its most common complication, PHN. The present study aimed to estimate the clinical and economic burden of
HZ and PHN in Valencia (Spain).
Methods: We prospectively analyzed the burden of HZ and PHN and their attributable costs in patients from 25
general practices in the Autonomous Community of Valencia serving 36,030 persons aged > 14 years. All patients
with a clinical diagnosis of HZ who attended these centers between December 1
st 2006 and November 30
th 2007
were asked to participate. Patients included were followed for 1 year.
Results: Of the 130 cases of HZ followed up, continued pain was experienced by 47.6% (95% confidence interval
(CI) = 35.6-56.7%) at 1 month after rash onset, by 14.5% (95% CI = 7.8-1.2%) at 3 months, by 9.0% (95% CI = 3.7-
14.3%) at 6 months, and by 5.9% (95% CI = 1.5-10.3%) at 12 months. The percentage of patients with PHN
increased with age, from 21.4% (95% CI = 8.3-40) in patients < 50 years to 59.2% (95% CI = 44.4-74) in patients ≥
70 years. The estimated total cost for the 130 HZ cases during the follow-up period was €49,160 ($67,349). Mean
cost per patient was €378 (range 53-2,830) ($517, range 73-3,877).
Conclusions: This study shows that PHN is a relatively common complication of HZ and that both conditions
combined give rise to a significant clinical and economic burden for patients and providers.
Background
Herpes zoster (HZ) is caused by the reactivation of a
latent infection with varicella zoster virus (VZV) after
primary chickenpox. HZ is characterized by a localized
eruption of vesicular lesions following the trajectory of a
s e n s o r yn e r v e ,a n db yt h ep r e s e n c eo fp a i na n di n f l a m -
mation of the affected nerve root [1].
The most frequent and debilitating complication of
HZ is postherpetic neuralgia (PHN), defined as neuro-
pathic pain that appears in the dermatomes affected by
the VZV infection. Pain associated with PHN can be
very severe and disabling and has a significant impact
on a patient’s quality of life [2].
Studies carried out in a number of countries have
shown that the incidence and severity of both HZ and
PHN increase significantly with age. The annual inci-
dence of HZ reported in population-based studies from
several countries ranged from 1.2 to 4.8 cases per 1,000
inhabitants/year. The lifetime risk of HZ can be as high
as 30% and increases markedly with age, affecting 50%
of people living to 85 years of age [3-11]. PHN affects
10-70% of patients with HZ. This wide range is partly
due to differences in the definition of PHN used in dif-
ferent studies and to the age range of the study
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Thus, in older patients, the prevalence of PHN among
patients with HZ is likely to be closer to the upper
boundary of that range [12].
In a previous study we reported an annual incidence
of HZ of 4.1 per 1,000 persons > 14 years of age (95%
confidence interval (CI) = 3.4-4.7) and described the
clinical and epidemiological characteristics of HZ in
Spain [13]. Our results were consistent with previous
findings by other authors in Spain [14,15], and in other
European [16-25] and non-European [8,10,11,26-28]
published studies.
Data on the epidemiology of HZ and PHN in Spain,
and on the associated costs are scarce; therefore, studies
are needed to evaluate the epidemiological and eco-
nomic impact of HZ and its most common complica-
t i o n ,P H N .T h ep r e s e n ts t u d ya i m e dt oe s t i m a t et h e
clinical and economic burden of HZ and PHN in the
primary health care system in Spain.
Methods
Design and setting
During a 1-year period (from 1
st December 2006 to 30
th
November 2007), a prospective study was carried out in
25 primary care general practitioner (GP) offices of the
public healthcare system of the Autonomous Commu-
nity of Valencia, Spain. We selected a convenience sam-
ple of 25 GP offices from rural (n = 6), urban (n = 10)
and semiurban (n = 9) areas that were considered to be
representative of this Autonomous Community.
Study population
During the study period, all patients > 14 years of age
who attended the investigators’ offices and were clini-
cally diagnosed with HZ were considered to be eligible
for inclusion. All patients who agreed to participate in
the study signed an informed consent form prior to
their participation.
For each patient, information was collected on demo-
graphic attributes, personal clinical history, clinical char-
acteristics of the HZ episode and associated
complications, medical visits and medication used to
treat the episode or its complications, and work absen-
teeism of the patients or their carers. The information
was obtained by interview with the patient and by
review of their medical records. No further medical vis-
its were planned for study purposes. Patients were tele-
phoned the day after the diagnosis, and four times
during follow-up (at 1, 3, 6 and 12 months after diagno-
sis). If the patients reported pain, they were contacted
monthly until disappearance of the pain. In those cases
where patients could not be accessed by phone, they
were visited at home by the study investigators in order
to establish their clinical status.
One hundred and forty six patients were diagnosed
and invited to participate. Those who declined to parti-
cipate (n = 16; 10.9%) were anonymously counted as HZ
cases to allow a real estimate of the incidence of the dis-
ease. Of the 130 participants, 1-year complete data was
obtained in 118 patients (90.8%). Thus, we had incom-
plete follow-up data for 12 patients (9.2%): six died
because of factors unrelated to HZ, two withdrew volun-
tarily from the study and four patients were lost to fol-
low-up.
Study measures and definitions
For the purpose of the present study we considered a
case of HZ as a localized eruption of vesicular lesions
following the trajectory of a sensory nerve as well as
pain and inflammation of the affected nerve root. This
definition was purely clinical since no other confirma-
tory test was necessary. A diagnostic test was performed
only if the GP determined that it was necessary.
We defined PHN as the presence of any pain, without
specifying a numerical threshold of intensity. We believe
that this definition is in accordance with most publica-
tions in this setting [27,29-32]. PHN is defined as pain
that persists beyond the acute phase of an HZ episode.
For this study, we considered PHN1, PHN3, PHN6 and
PHN12 as pain persisting 1, 3, 6 or 12 month(s), respec-
tively, after the onset of the rash. We defined “recur-
rence” as the development of cutaneous lesions on the
site of a previous eruption or at a different site, which
occurred beyond 3 months after the index HZ episode
was diagnosed. Recurrent HZ was not counted as a new
case.
Direct costs were evaluated as those derived from
medical care and medications, and included: 1) the
number of medical visits: primary care visits, primary
care emergency consultations, specialist visits, other pro-
fessional visits, hospitalizations, hospital emergencies; 2)
medications prescribed and/or consumed; and 3) diag-
nostic tests. We included the costs arising from symp-
toms occurring in the time period preceding the
vesicular rash, and all patients were asked, as per proto-
col, about these outpatient or hospital visits during the
initial interview.
The unit costs for the medical care variables were
obtained from the Valencian Community Official Regis-
tries (Presupuestos del Ejercicio 2008 de la Generalitat
Valenciana) [33] and the cost of medications was
obtained from the Vademecum
® 2007 Edition as a refer-
ence for each medication price [34]. Indirect costs were
defined as the productivity losses of patients and/or
their carers, which were calculated from the number of
hours of work missed related to HZ. The cost for an
effective working hour in 2007 was obtained from the
Spanish National Institute of Statistics [35]. For the
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patients were active workers (for which 60% of the cost
of medications is reimbursed by Spanish Social Security)
or pensioners (for which 100% is reimbursed) [36]. All
costs are presented in 2007 Euros (€).
The study was approved by the Clinical Research
Ethics Committee of the Dirección General de Salud
Pública/Centro Superior de Investigación en Salud Púb-
lica (CSISP) de la Comunidad Valenciana.
Sample size calculation: Statistical analysis
B a s e do na ne x p e c t e di n c i d e n c eo fH Zi nt h ea d u l t
population of 0.4% and a precision of 0.08%, we calcu-
lated that a minimum population of 23,600 people > 14
years of age should be monitored [6]. The study popula-
tion assigned to the 25 participating investigators repre-
sented a total of 36,030 individuals. This population
comprised 21,500 patients aged 15-49 years, 4,893
patients aged 50-59 years, 4,057 patients aged 60-69
years, and 5,580 patients aged ≥ 70 years. The age and
gender distribution of patients recruited in our study
was similar to that observed in the general population
(based on data from national Spanish registries [37]).
The percentage of patients with persisting pain during
follow-up was analyzed using the Kaplan-Meier method.
The incidence was calculated globally by gender and by
predefined age groups (< 50 years, 50-59 years, 60-69
years, and ≥ 70 years of age). Comparisons between
groups were performed using Student’s t-test for contin-
uous variables with Gaussian distribution.
Logistic regression was used to identify predictors of
t h eo c c u r r e n c eo fP H Na t1a n d3m o n t h s( d e p e n d e n t
variable). We considered as covariates those variables
that showed a P-value of ≤ 0.25 in the univariable analy-
sis (presence of PHN versus no PHN) and those clinically
relevant in previous studies (age, gender, prodromal pain,
extremities localization, sacrum localization, time from
symptoms onset until diagnosis, and time from rash
onset until diagnosis). We used an “enter” variable selec-
tion method. We obtained the odds ratio (OR) and 95%
CI. Model calibration was tested with the Hosmer-Leme-
show test. Model discrimination was evaluated with the
analysis of the area under the ROC (Receiver Operating
Characteristic) curve. All P-values < 0.05 were considered
to be statistically significant. All statistical analyses were
performed using the SPSS software package, version 17.0
(SPSS Inc., Chicago, IL, USA).
Results
Epidemiology of PHN
Baseline characteristics of study patients are presented
in Table 1. A total of 146 HZ patients were diagnosed
within the 1-year period, an annual incidence of 4.1
cases per 1,000 persons > 14 years (95 CI % = 3.4-4.7).
Median age was 63.5 years (range 19-94; interquartile
range 51-75 years) and the highest incidence was
observed in older patients (≥ 70 years of age), namely
11.1/1,000 population.
In the present study, only one case (1/130) of recur-
rence at the same site was reported at 7 months. No
recurrences (0/130) at different sites were observed.
Pain continued to be experienced by 47.6% of patients
at 1 month after rash onset (95% CI = 35.6-56.7%), by
14.5% (95% CI = 7.8-21.2%), at 3 months, by 9.0% (95%
CI = 3.7-14.3%) at 6 months, and by 5.9% (95% CI =
1.5-10.3%) at 12 months (Figure 1). The median dura-
tion of pain was 26.5 days (95% CI = 20-34). Figure 2
shows the percentage of patients with PHN at 1 month
and 3 months in each age group. The mean age of
patients who fulfilled the PHN definition at 1 month
was 66.7 years, and 61.7% of the patients were female.
In the case of PHN at 3 months, the mean age was 70.1
years, and 50% of the patients with PHN were female.
The percentage of patients developing PHN (at 1
month) increased with age from 21.4% (95% CI = 8.3-
40) in patients < 50 years to 59.2% (95% CI = 44.4-74)
in patients ≥ 70 years (Figure 2).
In the multivariate model, age (years) (OR = 1.04, P <
0.01) and time interval (days) between symptom onset
and clinical diagnosis (OR = 1.11, P < 0.01) were both
independently associated with PHN at 1 month. At 3
months, only age (OR = 1.04, P = 0.03) was found to be
associated with PHN. However, we did not observe a
significant association of gender or antiviral drug use
(both P > 0.05) with the occurrence of PHN.
Health care and medication costs of HZ disease
During the follow-up period, 130 cases of HZ generated a
total of 308 primary care visits (mean per patient = 2.37;
standard deviation (SD) = 1.99), 86 visits to the Emergency
Room in Primary Care Centers (mean per patient = 0.66;
SD = 1.04), 38 Specialist visits (mean per patient = 0.29;
SD = 1.08), 40 other professional (nurse, physiotherapist
and alternative medical practitioner) visits (mean per
patient = 0.31; SD = 2.82), 23 hospital Emergency Room
visits (for first medical contact for the diagnosis of HZ
before being attending the GP office, and for episodes of
severe pain) (mean per patient = 0.18; SD = 0.52), and 29
diagnostic tests (including X-ray studies (thorax and abdo-
men), blood and urine tests, electrocardiograms and ultra-
sound scans in patients with pain but no cutaneous
manifestations, before the HZ rash appeared) (mean per
patient = 0.22; SD = 0.64). No confirmation molecular
tests were performed. No hospitalizations for HZ disease
were observed during the study follow-up.
The total cost for the management of the 130 patients
included in the analysis during the 1-year follow-up per-
iod was €40,234 (US$55,120) for a Third-Party Payer
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($67,349) from a societal perspective, yielding an average
cost per patient of €309, SD = 308 ($423, SD = 422) and
€378, SD = 431 ($518, SD = 590), respectively. The most
important factor that contributed to the economic bur-
den of disease (Table 2) was medication (33% and 37%
of the cost from the TPP perspective and the societal
perspective, respectively) followed by GP visits (29% and
23% of the cost from the TPP perspective and the socie-
tal perspective, respectively), and Emergency in Primary
Care visits (18% and 15% of the cost from the National
Payer perspective and the societal perspective, respec-
tively) (Table 2).
Ninety-one percent of patients were prescribed anti-
virals, representing 77% of the total cost of medication.
Other medications used were anticonvulsants (12.2%),
analgesics (4.7%), antidepressants (0.6%), opioids (0.5%)
and corticoids (0.4%), accounting all together for 18.4%
of the total costs of medications. Total and mean costs
per age groups are summarized in Table 3.
Our study patients lost a total of 565 hours of work
(mean per patient = 4.35; SD = 25.99) and their carers
lost 6 hours of work (mean per patient = 0.05; SD = 0.53).
Cost of PHN1
Total cost of the management of patients with PHN1 was
significantly (P < 0.001) higher (total cost, €32,974
($45,110); mean per patient, €549 ($752), SD = €580
($795)) compared with the cost for patients without PHN
(total costs, €16,186 ($22,175)); mean per patient, €231
($316); SD = €107 ($147)). The most important factor
that contributed to the cost was medication (€10,923
($14,964); mean per patient, €182 ($249), SD = €182
($249) followed by GP visits (€6,686 ($9,160); mean per
Table 1 Baseline characteristics of study patients
Variable n = 130
Age, years, median (range) 63.5 (19-94)
Female gender, n (%) 83 (63.8)
Area of residence
Urban, n (%) 41 (31.5)
Semiurban, n (%) 39 (30)
Rural, n (%) 50 (38.5)
Predisposing clinical conditions† 60 (46.2)
Immunosuppressant* use, n (%) 3 (2.3)
Malignancy, n (%) 12 (9.2)
HIV, n (%) 0
Transplant, n (%) 1 (0.8)
Chronic disease*, n (%) 39 (30)
Trauma/burns/radiotherapy, n (%) 3 (2.3)
Other** 6 (4.6)
Not reflected in clinical history, n (%) 2 (1.5)
Complications†, n (%) 31 (23.8)
Ocular, n (%) 11 (8.5)
Bacterial superinfection, n (%) 7 (5.4)
Dysgeusia, n (%) 4 (3.1)
Hypoacusia, vertigo, tinnitus, n (%) 2 (1.5)
Dissemination, n (%) 2 (1.5)
Involvement of other organs, n (%) 1 (0.8)
Other‡, n (%) 12 (9.2)
Use of antiviral agents, n (%) 119 (91.5)
Time elapsed from symptom onset to diagnosis, days (SD) 6.3 (5.8)
SD: Standard deviation.
HIV: Human immunodeficiency virus.
* Administration of oral or systemic corticosteroids or chemotherapy treatment.
† Each patient may have more than one baseline clinical condition/complication.
* Chronic disease was defined as diabetes mellitus, chronic obstructive pulmonary disease, moderate or severe asthma, rheumatoid arthritis, chronic liver disease,
chronic kidney disease, congenital heart disease, and systemic lupus erythematosus.
** Other risk factors refer to multisystem atrophy, major depression, postsurgical stress, influenza, and polysubstance abuse.
‡ Other complications refer to lymphadenopathy, activity limitation, fungal infection in the herpes zoster area, allergic reactions to treatment, weight loss,
anorexia, vomiting, and diarrhea.
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Primary Care visits (€4,173 ($5,717); mean per patient,
€70 ($96), SD = €111 ($152)) (Table 4).
Cost of PHN3
Total cost of management of patients with PHN3 was
significantly higher (P < 0.001) (total costs, €14,786
($20,257); mean per patient, €821 ($1,125), SD = €681
($941)) compared with the cost for patients without
PHN (total costs, €34,373 ($47,091); mean per patient,
€307 ($421), SD = €328 ($449)). The most important
factor that contributed to the cost was medication
(€5,730 ($7,850); mean per patient, €318 ($436), SD =
€280 ($384)) followed by Emergency in Primary Care
visits (€2,421 ($3,317); mean per patient, €134 ($184),
SD = €165 ($226)) and GP visits (€2,393 ($3,278); mean
per patient, €133 ($182), SD = €91 ($125)) (Table 5).
None of the study patients was treated by pain clinics
during the one year follow-up. Table 6 presents detailed
information regarding the consumption of resources by
patients with PHN1 and PHN3.
Discussion
No previous study has provided current HZ epidemio-
logical data and a detailed estimate of the associated
costs in Spain. It is important to highlight that our
study was prospectively designed and patients’ symp-
toms were monitored periodically by phone until PHN
resolution. As mentioned above, no medical visits were
planned for study purposes in order to allow for a
more accurate estimate of healthcare resource con-
sumption associated with HZ management. Moreover,
this is the first study in Spain that provides informa-
tion about the cost of HZ and PHN on an outpatient
basis. Others have reported the cost of HZ in patients
admitted to hospital [38].
In our study the 1-year incidence of HZ was 4.1 per
1000 persons (95% CI = 3.4-4.7) in those aged > 14
years. The incidence of PHN was 47.6% at 1 month.
This percentage was higher than the figures reported in
retrospective studies in Europe (14.3% [all ages of sub-
jects] [39] to 19.5% [≥ 50 years of age] [24]) but similar
to that in a prospective study (51.2%) recently published
in a Mediterranean country [40]. In the USA, a ground-
breaking study by Yawn [27] reported that the incidence
of HZ in subjects > 22 years in the US was 3.6 per 1000
person-years (95% CI = 3.4-3.7). The incidence of PHN
in the same population was 82% when defined as pain
of at least 1 month duration. In the case of 3-month
PHN (PHN3), our results (14.5%) were similar to those
Figure 1 Kaplan-Meier method showing the percentage of patients with persisting pain during the follow-up.
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Figure 2 Percentage of patients developing postherpetic neuralgia (PHN) at 1 and 3 months per age groups (95% confidence
intervals are presented).
Table 2 Total cost* for patients included in the study with diagnosis of herpes zoster
TPP perspective** Societal perspective‡
Direct costsj Total Mean SD % Total Mean SD %
Primary care visits 11,521.24 88.62 56.14 28.64% 11,521.24 88.62 56.14 23.44%
Primary care emergencies 7,178.42 55.22 86.68 17.84% 7,178.42 55.22 86.68 14.60%
Specialist visits 1,726.48 13.28 41.76 4.29% 1,726.48 13.28 41.76 3.51%
Other professional visits
□ 662.80 5.10 46.72 1.65% 662.80 5.10 46.72 1.35%
Hospitalizations 0 0 0 0 0 0 0 0
Hospital emergencies 2,369.92 18.23 53.62 5.89% 2,369.92 18.23 53.62 4.82%
Diagnostic tests 625.25 4.81 13.92 1.55% 625.25 4.81 13.92 1.27%
Medication 13,443.62 103.41 132.38 33.41% 18,115.26 139.35 138.26 36.85%
Indirect costs#
Absenteeism from work 2,706.18 20.82 137.74 6.73% 6,887.35 52.98 316.86 14.01%
Carers † 0 0 0 0 73.14 0.56 6.41 0.15%
* In 2007 euros.
□ Other professionals: physiotherapist, nurses and alternative medical practitioners.
† Carers: those persons or relatives who took care of herpes zoster patients.
** TPP Perspective (Third-Party Payer = Spanish Social Security): public medical visits + diagnostic test + percentage that Spanish National Health System pays for
prescriptions.
‡ Societal perspective: TPP perspective items + percentage that patient pay for prescription + private medical visits + medication not included in the Spanish
National System + cost for lost hours of work.
j Direct costs: medical care and medications, and included: 1) the number of medical visits: primary care visits, primary care emergency consultations, specialist
visits, other professional visits, hospitalizations, hospital emergencies; 2) medications prescribed and/or consumed and 3) diagnostic tests.
# Indirect costs: productivity losses of patients and/or their carers, calculated from the number of hours of work missed due to herpes zoster.
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[23,24,40], and also to those reported in the USA [4,27].
Although differences were observed with regard to
PHN1 between our study and that of Yawn [27], the
incidence of HZ and PHN at 3 months was similar
though determined in slightly different populations (>
22 vs. > 14 years). We do not have a reason for the 1-
month difference as both study populations showed a
similar distribution of age and gender, both of which
have an effect on the incidence of PHN. Nevertheless,
the different study designs might have an impact in this
regard. The study by Yawn [27] was retrospective and
the present investigation was prospective to better esti-
mate the occurrence of PHN.
The main risk factor for developing PHN among
immunocompetent subjects in our study was age. An
increase in 1 year of age yielded a 4.2% increase in the
risk of PHN at 1 and 3 months. This finding has been
previously observed by other authors [23,24].
There is controversy as to whether gender can be con-
sidered an actual risk factor for PHN as some studies
found an association [24,39] while others did not [23].
Differences between genders, regarding perception and
response to pain, may explain the disparities [41], or a
higher GP attendance by women may play a part.
In our study the overall percentage of patients treated
with antivirals was high, namely 91%, when compared
with the proportion of patients (58.8%) in whom treat-
ment was initiated within 72 hours of the onset of rash
(following the current treatment recommendations).
However, this proportion was not substantially different
to that observed in other previously published studies,
such as the Oxman study [4]. In that study, the percen-
tage of patients treated with antiviral drugs ranged from
85.7% to 87.3%. Differences in study design might have
influenced the small differences between the studies.
In our study the prescription of antiviral therapy was
not associated with the occurrence of PHN, although it
should be stressed that a high percentage of patients
(41.2%) received antivirals beyond 72 hours after rash
onset. After adjusting for other co-variates, such as age
and presence of chronic illness, it was not found that
antivirals would act as a preventive measure for the
development of PHN.
This study also provides a recent estimate of the eco-
nomic burden of HZ and PHN in a developed country.
Given that the size of Spanish population age > 14 years
in 2007 was 38,443,352 inhabitants, and that the preva-
lence of HZ was 4.1 cases per 1,000 persons > 14 years
(95% CI = 3.4-4.7), we estimate a national cost of €59.6
million per year (95% CI = 49.4-68.3), which represents
0.06‰ of the 2007 gross national product (GNP).
In comparing with other European studies, our inves-
tigation found the cost of HZ to be €378 per patient,
roughly double the cost reported by Gautier [24] (103
GB Pounds [£] equivalent to €151), but was lower than
those reported by Davies [42] (£770, equivalent to
€1132), Edmunds [43] (£306 equivalent to €450) and
S c o t t[ 2 3 ]( £ 5 2 4 ,e q u i v a l e n tt o€770). The high cost
reported by Davies [42] could be due to the fact that
the patients attended a tertiary referral center with a
specialist pain clinic. We report a cost per PHN episode
of 549 € using the 1-month definition, similar to that
reported by Gautier [24] (£341, equivalent to €501).
Applying the 3-month PHN definition, we report a total
cost equal to €821 per patient while it was of £397
(€584) in Gautier’s study [24].
In the USA, the comparable study by Yawn [44] found
that the mean HZ-attributable cost was $782 (€531) for
those patients in an outpatient setting. In our study (no
hospitalizations were recorded) the mean cost was €378,
significantly lower than that reported in the Yawn study
[44]. For those patients who developed PHN, a mean
cost of $4,388 per patient (€3203) was obtained in the
Yawn study [44]. Again, this figure was substantially
higher than our estimate (€821). Noteworthy in the
Yawn’s study there were 66 HZ-related hospitalizations,
(with a mean length of stay of 5.1 days) compared to
none hospitalizations in our study. This could explain,
at least partially, the observed differences.
Comparisons between different studies from different
countries are controversial due to substantial disparities
in economic, demographic, cultural and institutional
(health sector) structures [45]. Moreover, the different
rate of antiviral prescribing (50% in the Gautier [24]
study vs. 91% in the present study) might have
accounted for some of the differences in the total cost
between the studies. This issue is in contrast with the
current recommendations of clinical consensus reports
and needs to be studied in detail separately [46].
Table 3 Total cost* for patients included in the study
with diagnosis of herpes zoster by age subgroups
TPP perspective** Societal perspective‡
Age Total Mean SD Total Mean SD
< 50 years 6,131.76 211.44 166.60 9,059.86 312.41 360.52
50-59 years 7,170.86 239.03 231.48 11,235.57 374.52 485.30
60-69 years 8,652.79 432.64 434.52 10,426.75 521.34 626.65
≥ 70 years 18,278.50 358.40 329.37 18,437.69 361.52 330.04
Total 40,233.91 309.49 307.47 49,159.86 378.15 430.67
P = 0.027 P = 0.401
* In 2007 Euros.
** TPP Perspective (Third-Party Payer = Spanish Social Security): public
medical visits + diagnostic test + percentage that Spanish National Health
System pays for prescriptions.
‡ Societal perspective: TPP perspective items + percentage that patient pay
for prescription + private medical visits + medication not included in the
Spanish National System + cost for lost hours of work.
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Page 7 of 12In line with Gautier’s study in Europe [24] and Yawn’s
study in the USA [44], the most important factor that
contributed to the economic burden was medication,
followed by general practitioner visits.
HZ and PHN have an important impact for the Span-
ish Health Service, society and the individual. Current
therapies and options do not completely alleviate the
acute pain, and fail to prevent PHN, and thus provides
preventive measures such as vaccination may be war-
ranted. Zoster vaccine has been shown to reduce the
burden of HZ by decreasing the incidence and symptom
severity, and it has also been shown to reduce the inci-
dence of PHN compared with placebo [4].
Our study has some limitations. First, those patients
with HZ who may have gone to a private practitioner
might not be detected in our study, leading to an under-
estimate of the disease; however, it can be presumed
that this proportion of patients would be small given
the free health care provision in Spain and the reimbur-
sement of drugs prescribed in public GP offices. In
Spain many patients directly attend Accident & Emer-
g e n c y( A & E )d e p a r t m e n t sw h e nt h e yp e r c e i v ead i s e a s e
Table 4 Cost* of herpes zoster and postherpetic neuralgia at 1 month
TPP perspective** Societal perspective‡
Direct costsj Total Mean SD Total Mean SD
Primary care visits With PHN 6,686.34 111.44 69.02 6,686.34 111.44 69.02
Without PHN 4,834.90 69.07 31.29 4,834.90 69.07 31.29
Primary care emergencies With PHN 4,173.50 69.56 111.00 4,173.50 69.56 111.00
Without PHN 3,004.92 42.93 56.38 3,004.92 42.93 56.38
Specialist visits With PHN 1,301.86 21.70 57.33 1,301.86 21.70 57.33
Without PHN 424.62 6.07 18.33 424.62 6.07 18.33
Other professional visits
□ With PHN 629.66 10.49 68.62 629.66 10.49 68.62
Without PHN 33.14 0.47 2.78 33.14 0.47 2.78
Hospitalizations With PHN 0 0 – 00 –
Without PHN 0 0 – 00 –
Hospital emergencies With PHN 2,060.80 34.35 72.65 2,060.80 34.35 72.65
Without PHN 309.12 4.42 21.02 309.12 4.42 21.02
Diagnostic tests With PHN 438.75 7.31 17.35 438.75 7.31 17.35
Without PHN 186.50 2.66 9.73 186.50 2.66 9.73
Medication With PHN 8,626.16 143.77 177.84 10,923.44 182.06 182.45
Without PHN 4,817.45 68.82 55.59 7,191.82 102.74 65.79
Indirect cost#
Absenteeism from work With PHN 2,706.18 45.10 200.92 6,686.22 111.44 461.46
Without PHN 0 0 0 201.14 2.87 9.94
Carers † With PHN 0 0 0 73.14 1.22 9.44
Without PHN 0 0 0 0 0 0
* In 2007 euros.
□ Other professionals: physiotherapist, nurses and alternative medical practitioners.
† Carers: those persons or relatives who took care of herpes zoster patients.
** TPP Perspective (Third-Party Payer = Spanish Social Security): public medical visits + diagnostic test + percentage that Spanish National Health System pays for
prescriptions.
‡ Societal perspective: TPP perspective items + percentage that patient pay for prescription + private medical visits + medication not included in the Spanish
National System + cost for lost hours of work.
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Page 8 of 12Table 5 Cost* of herpes zoster and postherpetic neuralgia at 3 months
TPP perspective Societal perspective
Direct costs
Total Mean SD Total Mean SD
Primary care visits With PHN 2,393.54 132.97 90.73 2,393.54 132.97 90.73
Without PHN 9,127.70 81.50 45.08 9,127.70 81.50 45.08
Primary care emergencies With PHN 2,420.63 134.48 164.81 2,420.63 134.48 164.81
Without PHN 4,757.79 42.48 58.21 4,757.79 42.48 58.21
Specialist visits With PHN 525.41 29.19 62.90 525.41 29.19 62.90
Without PHN 1,201.07 10.72 37.06 1,201.07 10.72 37.06
Other professional visits With PHN 33.14 1.84 5.36 33.14 1.84 5.36
Without PHN 629.66 5.62 50.31 629.66 5.62 50.31
Hospitalizations With PHN 0 0 – 00 –
Without PHN 0 0 – 00 –
Hospital emergencies With PHN 1,133.44 62.97 100.83 1,133.44 62.97 100.83
Without PHN 1,236.48 11.04 37.52 1,236.48 11.04 37.52
Diagnostic tests With PHN 209.85 11.66 17.72 209.85 11.66 17.72
Without PHN 415.40 3.71 12.97 415.40 3.71 12.97
Medication With PHN 4,718.82 262.16 282.99 5,730.03 318.34 279.66
Without PHN 8,724.80 77.90 57.95 12,385.23 110.58 64.87
Indirect costs
Absenteeism from work With PHN 965.45 53.64 227.56 2,340.48 130.03 515.71
Without PHN 1,740.73 15.54 117.96 4,546.87 40.60 273.55
Carers With PHN 0 0 0 0 0 0
Without PHN 0 0 0 73.14 0.65 6.91
* In 2007 Euros.
Table 6 Resource consumption PHN* at 1 and 3 months
PHN AT 1 MONTH PHN AT 3 MONTHS
Total Mean per patient SD Total Mean per patient SD
Primary care visits With
PHN
192 3.20 2.48 72 4 3.27
Without PHN 116 1.66 1.02 236 2.11 1.57
Primary care emergencies With
PHN
50 0.83 1.33 29 1.61 1.97
Without PHN 36 0.51 0.68 57 0.51 0.7
Specialist visits With
PHN
31 0.52 1.53 12 0.67 1.68
Without PHN 7 0.10 0.30 26 0.23 0.95
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Page 9 of 12as “serious”. This might have underestimated our inci-
dence result. Any way, we consider that this underesti-
mation should not be of considerable importance as in
the Valencian Community, usually patients diagnosed by
the A&E departments physicians or private specialists,
in addition, attend to their primary care GP for pre-
scription and reimbursement of medication, thus being
susceptible to be recruited in the study.
Second, our study is not a population-based study but
is based on a convenience sample of primary healthcare
GP offices, so extrapolation of our results to the general
adult population should be made with caution. Finally,
in our study the costs related to working time lost
showed a wide range of variation as indicated by a high
standard deviation, thus making interpretation difficult.
Conclusions
HZ and PHN are prevalent diseases in Spain whose inci-
dence increases with age. HZ and PHN have a significant
clinical and economic burden. Randomized controlled
trials would be appropriate and necessary to investigate
the role of antiviral therapy in preventing PHN when pre-
scribed more than 72 hours after rash onset.
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Table 6 Resource consumption PHN* at 1 and 3 months (Continued)
Other professional visits
□ With PHN 38 0.63 4.14 2 0.11 0.32
Without PHN 2 0.03 0.17 38 0.34 3.04
Hospitalizations With
PHN
00 – 00-
Without PHN 0 0 – 00-
Hospital emergencies With
PHN
20 0.33 0.71 11 0.61 0.98
Without PHN 3 0.04 0.20 12 0.11 0.36
Diagnostic tests With
PHN
21 0.35 0.80 10 0.56 0.78
Without PHN 8 0.11 0.44 19 0.17 0.6
* PHN: Postherpetic neuralgia.
□ Other professionals: physiotherapist, nurses and alternative medical practitioners.
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